FDA approves breakthrough drug for metastatic pancreatic cancer
By The BriefBrief
The FDA approved daraxonrasib, to be sold as Rasonque by Revolution Medicines, for patients with metastatic pancreatic cancer. In a late-stage trial of 500 people, median overall survival nearly doubled to more than 13 months versus about 6.7 months with standard chemotherapy.
WHO:FDA; Revolution Medicines; Dr. Brian Wolpin (Dana-Farber Cancer Institute)
WHAT:Approval of daraxonrasib (Rasonque), a daily pill targeting multiple RAS protein forms, for metastatic pancreatic cancer.
WHEN:Aug 27, 2026
WHERE:CA
WHY:The FDA approved the drug after late-stage trial results showed substantially improved overall survival versus standard chemotherapy.
Reporting from 1 identified publisher for this event.
